---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007181"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2026-09-16T11:00:44+00:00"
generated_at: "2026-09-16T11:05:15.201537+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Xenetic to acquire Santersus in all-stock deal; combined company to trade as SNTS

## Summary
- Share exchange: Xenetic acquires all Santersus shares; Santersus holders to own ~85% of combined company.
- Combined company to rename Santersus Bio, Inc. and list on Nasdaq under ticker SNTS.
- Post-close board: 8 members (6 Santersus, 2 Xenetic); Santersus CEO James Ladtkow to lead.
- Deal includes $500,000 termination fee and 180-day lock-up for officers/directors/stockholders.
- Pipeline: four first-in-class programs incl. sepsis and SLE with FDA Breakthrough Device Designation.

## SEC filing metadata
- accession: 0001683168-26-007181
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2026-09-16T11:00:44+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/0001683168-26-007181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007181
- JSON: https://secwatch.observer/filing/0001683168-26-007181.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.